scholarly journals Open-label randomized trial of titrated disease management for patients with hypertension: Study design and baseline sample characteristics

2016 ◽  
Vol 50 ◽  
pp. 5-15 ◽  
Author(s):  
George L. Jackson ◽  
Morris Weinberger ◽  
Miriam A. Kirshner ◽  
Karen M. Stechuchak ◽  
Stephanie D. Melnyk ◽  
...  
Keyword(s):  
Disease Management ◽  
Randomized Trial ◽  
Study Design ◽  
Open Label ◽  
Sample Characteristics ◽  
Baseline Sample

scholarly journals Effects of physical activity calorie expenditure (PACE) labeling: study design and baseline sample characteristics

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Anthony J. Viera ◽  
Laura Tuttle ◽  
Emily Olsson ◽  
Julie Gras-Najjar ◽  
Ziya Gizlice ◽  
...  
Keyword(s):  
Physical Activity ◽  
Study Design ◽  
Sample Characteristics ◽  
Calorie Expenditure ◽  
Baseline Sample

scholarly journals Tailored Case Management for Diabetes and Hypertension (TEACH-DM) in a community population: Study design and baseline sample characteristics

2013 ◽  
Vol 36 (1) ◽  
pp. 298-306 ◽  
Author(s):  
Matthew J. Crowley ◽  
Hayden B. Bosworth ◽  
Cynthia J. Coffman ◽  
Jennifer H. Lindquist ◽  
Alice M. Neary ◽  
...  
Keyword(s):  
Case Management ◽  
Study Design ◽  
Population Study ◽  
Community Population ◽  
Sample Characteristics ◽  
Baseline Sample

Randomized Trial of Home-based Disease Management for Patients with Heart Failure (J-HOMECARE): Study Design

2008 ◽  
Vol 14 (7) ◽  
pp. S167
Author(s):  
Miyuki Makaya ◽  
Hisashi Matuo ◽  
Yoshiko Nishino ◽  
Shigeo Kakinoki ◽  
Shigeru Takechi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Disease Management ◽  
Randomized Trial ◽  
Study Design ◽  
Home Based ◽  
Patients With Heart Failure

Study design, result reporting and publication of late-stage cardiovascular trials

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
C Kapelios ◽  
H Naci ◽  
P Vardas ◽  
E Mossialos
Keyword(s):  
Study Design ◽  
Late Stage ◽  
Late Phase ◽  
Phase Iii ◽  
Open Label ◽  
Explanatory Factors ◽  
Study Protocols ◽  
Study Results ◽  
Artery Disease ◽  
Design Result

Abstract Introduction Preregistration of study protocols in publicly accessible databases is required for publication of study results in high-impact medical journals. Nonetheless, data on the characteristics of clinical trials registered in these databases and their outcome, in terms of result reporting and publication are limited. Methods The purpose of this study was to perform a comprehensive analysis of the characteristics of late-stage, cardiovascular disease (CVD) trials registered in Clinicaltrials.gov. We searched for interventional, late-phase (annotated as phase III) CVD studies in adults first posted after 1/1/2013 and completed up to 31/12/2018. Data on study design, result reporting, result spinning and publication were collected, and potential associations with a pre-defined set of explanatory factors were examined. Results The search yielded 352 studies. One hundred were excluded from further analysis because they were misclassified as CVD studies, while 2 were excluded as duplicate entries. In total, 250 CVD trials were included in the analysis. The most commonly studied fields were hypertension, coronary artery disease and heart failure. Of these, 193 (77.2%) were randomized studies, 99 (39.6%) open label designs, and 126 (50.4%) had industry as main sponsor. 179 trials (71.6%) evaluated the effect of drugs and 27 (10.8%) evaluated devices. Industry-funded trials focused on patent-protected drugs and devices more often than non-industry-funded trials (72.0% vs. 30.6%, P<0.001 and 55.0% vs. 26.3%, P=0.033, respectively). Sixty three studies (25.2%) had results posted on clinicaltrials.gov, and 116 (46.4%) had results published in the scientific literature. No clear indication of result spinning was found in 96 (85%) of published studies. In multivariate analysis, industry sponsorship was statistically significantly associated with results posting (OR: 3.56; 95% CI:1.67–7.60, P=0.001) and publication (OR: 0.41; 95% CI:0.23–0.75, P=0.004). Results spinning was associated with confirmation of the primary hypothesis (OR: 0.23; 95% CI: 0.07–0.75, P=0.015) and results posting (OR: 0.08; 95% CI: 0.01–0.65, P=0.018). Conclusions Among late-stage cardiovascular trials only 1/4 had their results posted on clinicaltrials.gov and less than half had results published. Industry sponsors were more likely to invest in research on patent-protected drugs and devices than were non-industry sponsors. Having industry as a sponsor was independently associated with increased likelihood of results posting, but decreased likelihood of results publication. Results reporting was significantly associated with lower risk of results spinning. Funding Acknowledgement Type of funding source: None

A controlled randomized trial of atypical depression: Study design and patient characteristics

1994 ◽  
Vol 35 (9) ◽  
pp. 617
Author(s):  
R.B. Jarrett ◽  
M.H. Schaffer ◽  
M.M. Down ◽  
Q.C. Cheng ◽  
C. Judd ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Study Design ◽  
Patient Characteristics ◽  
Atypical Depression

Prevention of common mental disorders in employees – Conception, study design and sample characteristics of a multi-target survey

2016 ◽  
Vol 4 (2) ◽  
pp. 88-95 ◽  
Author(s):  
Martina Michaelis ◽  
Rahna Lange ◽  
Florian Junne ◽  
Eva Rothermund ◽  
Stephan Zipfel ◽  
...  
Keyword(s):  
Mental Disorders ◽  
Study Design ◽  
Common Mental Disorders ◽  
Sample Characteristics

scholarly journals Tribendimidine and Albendazole for Treating Soil-Transmitted Helminths, Strongyloides stercoralis and Taenia spp.: Open-Label Randomized Trial

2008 ◽  
Vol 2 (10) ◽  
pp. e322 ◽  
Author(s):  
Peter Steinmann ◽  
Xiao-Nong Zhou ◽  
Zun-Wei Du ◽  
Jin-Yong Jiang ◽  
Shu-Hua Xiao ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Strongyloides Stercoralis ◽  
Open Label ◽  
Soil Transmitted Helminths
Sign in / Sign up

Export Citation Format

Share Document